Published in Oncotarget on July 26, 2016
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res (2016) 0.80
Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. Int J Mol Sci (2017) 0.75
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci (2017) 0.75
Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget (2017) 0.75
Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. Genome Med (2016) 0.75
Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? Transl Androl Urol (2016) 0.75
Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer (2017) 0.75
Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J (2017) 0.75
The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. Mol Diagn Ther (2017) 0.75
Circulating Tumor DNA as Biomarkers for Cancer Detection. Genomics Proteomics Bioinformatics (2017) 0.75
Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci (2010) 5.17
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (2012) 4.01
Emerging roles of proteases in tumour suppression. Nat Rev Cancer (2007) 3.81
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 3.41
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33
Nanopore DNA sequencing with MspA. Proc Natl Acad Sci U S A (2010) 3.17
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Decoding long nanopore sequencing reads of natural DNA. Nat Biotechnol (2014) 2.77
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 2.65
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol (2015) 2.64
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem (2001) 2.48
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev (1999) 2.21
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 2.18
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol (2015) 2.12
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A (2013) 2.05
Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol (2011) 1.86
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer (2015) 1.58
Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol (1994) 1.55
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev (1994) 1.48
PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness. Prostate (2013) 1.43
Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res (2014) 1.43
High fragmentation characterizes tumour-derived circulating DNA. PLoS One (2011) 1.42
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res (2010) 1.28
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol (2014) 1.28
Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol (2013) 1.27
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2014) 1.24
Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res (2010) 1.24
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med (2014) 1.24
The origin of circulating free DNA. Clin Chem (2007) 1.24
Nanopore sequencing: from imagination to reality. Clin Chem (2014) 1.23
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
CEA serum levels in non-neoplastic disease. Int J Biol Markers (1992) 1.21
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 1.18
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut (2015) 1.17
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med (2012) 1.16
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer (2014) 1.14
Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol (2011) 1.13
Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem (2008) 1.13
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12
Cancer biomarkers: Written in blood. Nature (2014) 1.10
Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer (2013) 1.07
The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. Oncotarget (2014) 1.06
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep (2015) 1.04
Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol Histopathol (1999) 1.04
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer (2013) 1.03
Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer (2011) 1.02
Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget (2014) 1.02
Prostate tissue and serum markers. Adv Clin Path (2000) 1.01
The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct (2010) 0.99
Circulating tumor-derived DNA is shorter than somatic DNA in plasma. Proc Natl Acad Sci U S A (2015) 0.99
Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer (2014) 0.97
Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy (2015) 0.95
Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol (2014) 0.95
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget (2015) 0.93
Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med (2010) 0.93
Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma. J Immunol Res (2014) 0.93
Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia (2014) 0.92
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies. Clin Chem (2015) 0.91
Cancer progression mediated by horizontal gene transfer in an in vivo model. PLoS One (2012) 0.91
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat (2014) 0.91
Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg (1998) 0.90
Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One (2012) 0.89
Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Oncotarget (2015) 0.89
Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol (2014) 0.86
Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer (2014) 0.86
Novel molecular insights from routine genotyping of colorectal carcinomas. Hum Pathol (2015) 0.84
Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev Mol Diagn (2014) 0.84
Functionality of circulating DNA: the hypothesis of genometastasis. Ann N Y Acad Sci (2001) 0.84
The emergence of nanopores in next-generation sequencing. Nanotechnology (2015) 0.82
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer. Br J Clin Pharmacol (2014) 0.81
The promise of nanopore technology: Nanopore DNA sequencing represents a fundamental change in the way that genomic information is read, with potentially big savings. IEEE Pulse (2014) 0.80
DNA sequencing and bar-coding using solid-state nanopores. Electrophoresis (2012) 0.79
Biological role of cell-free nucleic acids in cancer: the theory of genometastasis. Crit Rev Oncog (2013) 0.79
Loss of a reporter gene for green fluorescent protein during tumor progression suggests the recruitment of host cells in rats with experimentally induced colon cancer. Histol Histopathol (2008) 0.78
Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats. Cancer Lett (2005) 0.78
Breast cancer: Tracking ctDNA to evaluate relapse risk. Nat Rev Clin Oncol (2015) 0.78
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Semin Radiat Oncol (2015) 0.77
IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer. Stem Cells (2016) 0.89
Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology (2016) 0.81
Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis. PLoS One (2014) 0.80
MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer Res (2016) 0.78
Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma. Oncotarget (2016) 0.77
SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology (2016) 0.75